Increased metastatic potential of residual carcinoma after transarterial embolization in rat with McA-RH7777 hepatoma

Oncology Reports

Volumn 31, Issue 1, 2014, Pages 95-102

  Wang, Guang Zhi ^a   Fang, Zhu Ting ^a,b   Zhang, Wei ^a   Qu, Xu Dong ^a   Qian, Sheng ^a   Liu, Rong ^a   Wang, Jian Hua ^a  

^a FUDAN UNIVERSITY   (China)

^b FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Embolization; Epithelial mesenchymal transition; Hepatocellular carcinoma; Hypoxia inducible factor 1 ; Metastasis

Indexed keywords

GREEN FLUORESCENT PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IODINATED POPPYSEED OIL; NERVE CELL ADHESION MOLECULE; UVOMORULIN; VIMENTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ARTIFICIAL EMBOLISM; CANCER CELL CULTURE; CANCER TRANSPLANTATION; CATHETER; CELL HYPOXIA; CELL INVASION; CONTROLLED STUDY; FLUORESCENCE IMAGING; GASTRODUODENAL ARTERY; IN VITRO STUDY; IN VIVO STUDY; LAPAROTOMY; LIVER CELL CARCINOMA; LUNG METASTASIS; MALE; METASTASIS POTENTIAL; MINIMAL RESIDUAL DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TUMOR VOLUME; UPREGULATION;

ANIMALS; ARYL HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATOR; CADHERINS; CARCINOMA, HEPATOCELLULAR; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOEMBOLIZATION, THERAPEUTIC; EPITHELIAL-MESENCHYMAL TRANSITION; ETHIODIZED OIL; GREEN FLUORESCENT PROTEINS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INFUSIONS, INTRA-ARTERIAL; LIVER; LIVER NEOPLASMS; MALE; NEOPLASM INVASIVENESS; NEOPLASM, RESIDUAL; RATS; RATS, INBRED BUF; TREATMENT OUTCOME; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VIMENTIN;

EID: 84891916618     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2820     Document Type: Article

References (39)

1. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56: 908-943, 2012.
2. El-Serag HB: Hepatocellular carcinoma. N Engl J Med 365: 1118-1127, 2011.
3. Forner A, Llovet JM and Bruix J: Hepatocellular carcinoma. Lancet 379: 1245-1255, 2012.
4. Hasegawa K, Makuuchi M, Takayama T, et al: Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey. J Hepatol 49: 589-594, 2008.
5. Chen MS, Li JQ, Zheng Y, et al: A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 243: 321-328, 2006.
6. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390, 2008.
7. Fernandez M, Semela D, Bruix J, Colle I, Pinzani M and Bosch J: Angiogenesis in liver disease. J Hepatol 50: 604-620, 2009.
8. Llovet JM, Schwartz M and Mazzaferro V: Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 25: 181-200, 2005.
9. Sala M, Fuster J, Llovet JM, et al: High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation. Liver Transpl 10: 1294-1300, 2004.
10. Llovet JM and Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37: 429-442, 2003.
11. Lo CM, Ngan H, Tso WK, et al: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35: 1164-1171, 2002.
12. Virmani S, Rhee TK, Ryu RK, et al: Comparison of hypoxia-inducible factor-1α expression before and after transcatheter arterial embolization in rabbit VX2 liver tumors. J Vasc Interv Radiol 19: 1483-1489, 2008.
13. Wang B, Xu H, Gao ZQ, Ning HF, Sun YQ and Cao GW: Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol 49: 523-529, 2008.
14. Sergio A, Cristofori C, Cardin R, et al: Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol 103: 914-921, 2008.
15. Shim JH, Park JW, Kim JH, et al: Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci 99: 2037-2044, 2008.
16. Friedl P and Wolf K: Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 3: 362-374, 2003.
17. Thiery JP and Sleeman JP: Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7: 131-142, 2006.
18. Polyak K and Weinberg RA: Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9: 265-273, 2009.
19. van Zijl F, Zulehner G, Petz M, et al: Epithelial-mesenchymal transition in hepatocellular carcinoma. Future Oncol 5: 1169-1179, 2009.
20. Choi SS and Diehl AM: Epithelial-to-mesenchymal transitions in the liver. Hepatology 50: 2007-2013, 2009.
21. Copple BL: Hypoxia stimulates hepatocyte epithelial to mesenchymal transition by hypoxia-inducible factor and transforming growth factor-β-dependent mechanisms. Liver Int 30: 669-682, 2010.
22. Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2: 442-454, 2002.
23. De Larco JE, Wuertz BR, Manivel JC and Furcht LT: Progression and enhancement of metastatic potential after exposure of tumor cells to chemotherapeutic agents. Cancer Res 61: 2857-2861, 2001.
24. Ankoma-Sey V, Wang Y and Dai Z: Hypoxic stimulation of vascular endothelial growth factor expression in activated rat hepatic stellate cells. Hepatology 31: 141-148, 2000.
25. Kan Z, Phongkitkarun S, Kobayashi S, et al: Functional CT for quantifying tumor perfusion in antiangiogenic therapy in a rat model. Radiology 237: 151-158, 2005.
26. Maataoui A, Qian J, Mack MG, et al: Liver metastases in rats: chemoembolization combined with interstitial laser ablation for treatment. Radiology 237: 479-484, 2005.
27. Ramsey DE, Kernagis LY, Soulen MC and Geschwind JF: Chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol 13: S211-S221, 2002.
28. Harris AL: Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47, 2002.
29. 2 sensing. Science 292: 464-468, 2001.
30. Brahimi-Horn MC, Chiche J and Pouyssegur J: Hypoxia and cancer. J Mol Med (Berl) 85: 1301-1307, 2007.
31. Sendoel A, Kohler I, Fellmann C, Lowe SW and Hengartner MO: HIF-1 antagonizes p53-mediated apoptosis through a secreted neuronal tyrosinase. Nature 465: 577-583, 2010.
32. Daskalow K, Rohwer N, Raskopf E, et al: Role of hypoxia-inducible transcription factor 1α for progression and chemosensitivity of murine hepatocellular carcinoma. J Mol Med (Berl) 88: 817-827, 2010.
33. Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890, 2009.
34. Gupta GP and Massague J: Cancer metastasis: building a framework. Cell 127: 679-695, 2006.
35. Gupta S, Kobayashi S, Phongkitkarun S, Broemeling LD and Kan Z: Effect of transcatheter hepatic arterial embolization on angiogenesis in an animal model. Invest Radiol 41: 516-521, 2006.
36. Liang B, Zheng CS, Feng GS, et al: Correlation of hypoxia-inducible factor 1α with angiogenesis in liver tumors after transcatheter arterial embolization in an animal model. Cardiovasc Intervent Radiol 33: 806-812, 2010.
37. Maataoui A, Qian J, Vossoughi D, et al: Transarterial chemo embolization alone and in combination with other therapies: a comparative study in an animal HCC model. Eur Radiol 15: 127-133, 2005.
38. Abou-Alfa GK: TACE and sorafenib: a good marriage? J Clin Oncol 29: 3949-3952, 2011.
39. Acloque H, Adams MS, Fishwick K, Bronner-Fraser M and Nieto MA: Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest 119: 1438-1449, 2009.